Medical professionals are expressing concern over a Danish company’s proposal to make its popular weight-loss medication accessible to obese children. This request has ignited a debate within the health community.

Novo Nordisk’s CEO, Mike Doustdar, has urged the federal government to broaden the taxpayer subsidy for their well-known drug, Ozempic. However, general practitioners argue that there might be more appropriate alternatives available.

Doustdar believes Australia possesses the necessary resources to not only address obesity but to prevent it on a large scale. “It’s becoming increasingly critical as our youth worldwide are growing more obese,” he stated. “We must seek effective solutions.”

During a recent speech, Doustdar emphasized the importance of creating healthier environments and schools, as well as promoting exercise and balanced diets as fundamental strategies in combating obesity. However, he also highlighted the company’s commitment to ensuring their products are safe and effective for adolescents through rigorous testing.

“And the first and foremost solutions are some of the things I spoke to in my speech, healthier environments, healthier schools, taking care of exercise and food intake.

“But we are also, of course, making sure that our products are being tested and tried on adolescents and making sure that they’re safe. 

“So if support and help is needed on that front, it is also available so we don’t discriminate the age.”

Wright said “we certainly need more evidence” before going down that path, especially when the company’s own advertising says Ozempic is not for children.

Subsidising the category of drugs on a massive scale would likely cripple the federal health budget.

NEVER MISS A STORY: Get your breaking news and exclusive stories first by following us across all platforms.